<1xbet 후기ad prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 후기
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2018
  5. Otsuka subsidiary Avanir and Optinose agree to terminate license agreement for migraine treatment ONZETRA®Xsail®

Otsuka Pharmaceutical 1xbet 후기., Ltd.

Pharmaceuticals
December 11, 2018

Otsuka subsidiary Avanir and Optinose agree to terminate license agreement
for migraine treatment ONZETRA®Xsail®

Otsuka Pharmaceutical Co., Ltd. today announces that its U.S.-based indirect subsidiary Avanir Pharmaceuticals, Inc. has agreed with Optinose, Inc. to return to Optinose t1xbet 후기 rights in North America to ONZETRA®Xsail® for t1xbet 후기 acute treatment of migraines in adults.

Avanir compre1xbet 후기nsively reevaluated t1xbet 후기 U.S. migraine medication market. As a result, t1xbet 후기 decision was made to terminate t1xbet 후기 licensing agreement.

Previous
Next
Latest Pharmaceutical Business related News Releases
Most Recent Releases